Scheduling 7-OH is a necessary step to ensure oversight, prevent abuse, and safeguard the public from dangerous and unregulated products.
Support federal scheduling of concentrated synthetic 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance.
Occurrences
Evidence
The article says federal anti-7-OH directives have intensified the dispute and quotes the administration as working to "address the dangers posed by synthetic and highly concentrated 7-hydroxymitragynine ('7OH') products," while the industry waits to see whether federal prohibition will follow.
Assessments
The available evidence indicates that a broader federal push to address synthetic and highly concentrated 7-hydroxymitragynine products was still active as of June 15, 2026, but it does not show that concentrated synthetic 7-OH had been formally scheduled as a Schedule I controlled substance. It also does not identify Bilirakis as having written, sponsored, or materially advanced a completed federal scheduling action. Because the promised outcome remained pending and Bilirakis-specific delivery evidence is absent, the promise is best scored as unresolved rather than delivered, partial, or never.